期刊文献+

顶空气相色谱法测定阿哌沙班原料药中有机溶剂残留 被引量:4

Determination of residual organic solvents in Apixaban bulks drug by headspace gas chromatography
原文传递
导出
摘要 目的建立测定阿哌沙班原料药中可能残留的12种有机溶剂(甲醇、乙醇、丙酮、异丙醇、叔丁基甲醚、二氯甲烷、醋酸乙酯、四氢呋喃、三乙胺、原甲酸三甲酯、吗啉、N,N-二甲基甲酰胺)的检测方法。方法采用顶空气相色谱法,色谱柱为DB-624毛细管柱(30.0 m×0.53 mm×3.00μm),载气为高纯度氮气;顶空温度为100℃,顶空平衡时间为20 min;柱温40℃,维持6 min,以20℃/min升至220℃,维持10 min;氢火焰离子化检测器(FID),进样口温度为250℃,检测器温度为250℃,体积流量为2.8 m L/min,分流比为5:1。结果在考察的浓度范围内线性关系良好(r=0.999 4~0.999 9),12种残留溶剂均完全分离,精密度试验RSD值以及被测组分的平均回收率均符合要求。结论该气相色谱法操作简单,准确度、灵敏度高,可用于检测阿哌沙班原料药中残留的有机溶剂。 Objective To establish a method for determination of the twelve residual organic solvents, including methanol, ethanol, acetone, isopropanol, ten-Butyl methyl ether, dichloromethane, aceticether, tetrahydrofuran, triethylamine,trimethylorthofor-Mate, morpholine, N,N-Dimethylformamide in Apixaban bulks drug. Methods Gas head-space chromatography was applied to this study. The eolunm was DB-624 silica capillary column (30.0 m × 0.53 mm × 3.00 μm) and the carrier gas was high purity nitrogen; The vial temperature was 100 ℃, and the vial time was 20 min. The Column temperature was kept at 40℃ for 6 min, then the temperature was raised to 220 ℃ at the rate of 20 ℃/min and subsequently sustained for 10 min. FID detector temperature and injection temperature were both 250 ℃. The N2 flow rate was 2.8 mL/min. Split ratio was 5:1. Results Twelve kinds of solvents were completely separated and determined with a good linearity (r = 0.9994-0.9999).The RSD values of precision experiments and the average recovery was in line with the requirements. Conclusion Theanalytieal method is simple, accurate and sensitive, which could be used for determination of residual organic solvents in Apixaban bulks drug.
出处 《药物评价研究》 CAS 2017年第1期63-67,共5页 Drug Evaluation Research
关键词 阿哌沙班 顶空气相色谱 有机残留溶剂 Apixaban headspace gas chromatography residual organic solvents
  • 相关文献

参考文献1

二级参考文献28

  • 1Hirsh J,Dalen J,Anderson DR,et al.Oral anticoagulants:mechanism of action,clinical effectiveness,and optimal therapeutic range[J].Chest,2001,119(1):8S-21S. 被引量:1
  • 2McBride BF.A preliminary assessment of the critical differences between novel oral anticoagulants currently in development[J].J Clin Pharmacol,2005,45(9):1004-7. 被引量:1
  • 3Gómez-Outes A,Lecumberri R,et al.New Anticoagulants:Focus on Venous Thromboembolism[J].Curr Vasc Pharmacol,2009,7(3):309-29. 被引量:1
  • 4Perzbom E,Strassburger J,Wilmen A,et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral,direct factor Xa inhibitor[J].J Thromb Haemost,2005,3(3):514-21. 被引量:1
  • 5Wong PC,Crain EJ,Xin B,et al.Apixaban,an oral,direct and highly selective factor Xa inhibitoc in vitro,antithrombotic and antihemostatic studies[J].J Thromb Haemosy,2008,6 (5):820-9. 被引量:1
  • 6Eriksson BI,Quinlan DJ,Weitz JI Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development[J].Clin Pharmacokinet,2009,48 (1):1-22. 被引量:1
  • 7Saiah E,Soares C.Small molecule coagulation cascade inhibitors in the clinic[J].Curr Top Med Chem,2005,5(16):1677-95. 被引量:1
  • 8Turpie AG.Oral,direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases[J].Arterioscler.Thromb Vase Biol,2007,27 (6):1238-47. 被引量:1
  • 9Furugobri T,Isobe K,Honda Y,et al.DU-176b,a potent and orally active factor Xa inhibitor:in vitro and in vivo pharmacological profiles[J].J Thromb Haemost,2008,6(9):1542-9. 被引量:1
  • 10青爱国 武建卓.抗凝血的低分子量肽类似物.生命的化学,2008,28(4):395-8. 被引量:1

共引文献8

同被引文献36

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部